Please login to the form below

Not currently logged in
Email:
Password:

Ipsen reveals new strategy

Ipsen has published a comprehensive review of its future corporate strategy

Ipsen has unveiled its latest business strategy, which will see it invest in research and grow its operations in the US.

Marc de Garidel, chairman and chief executive of Ipsen, said: "Our strategy is threefold: first, increase focus through the creation of a new franchise-based organisation and increase R&D specialisation on two innovative and differentiated technological platforms, peptides and toxins. Second, within areas of focus, increase significant investments to enhance our research and commercial competitiveness.

"Last, leverage our international footprint, particularly in the USA and in the pharmerging markets, to gain global market share. We thus aspire at more than doubling our 2010 revenues and tripling our 2010 EBIT by 2020."

The company revealed that it expects to record one-off pre-tax costs of up to €100m in 2011 and 2012 related to the transfer of the US commercial operations to the East Coast, the closure of the Barcelona R&D site and other one-off costs related to the implementation of the strategy and of the new organisation.

9th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics